• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Cybin Inc.

    3/5/26 6:04:24 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HELP alert in real time by email
    6-K 1 form6k.htm FORM 6-K Cybin Inc.: Form 6-K - Filed by newsfilecorp.com

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of March, 2026.

    Commission File Number: 001-40673



    Cybin Inc.
    (Exact Name of Registrant as Specified in Charter)

    100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9

    (Address of principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

    Form 20-F □  Form 40-F ⊠


    EXPLANATORY NOTE

    Cybin Inc. (the "Company") is furnishing this Form 6-K (the "Form 6-K") solely to incorporate by reference into the Company's Registration Statement on Form F-10 (File No. 333-292294) (i) Exhibit 99.1 to this Form 6-K, which were previously filed with the Form 6-K dated February 10, 2026, and (ii) Exhibits 99.2-99.4 to this Form 6-K, which were previously filed with the Form 6-K dated February 13, 2026 (collectively, the "Original Form 6-Ks"). Following the furnishing of the Original Form 6-Ks, the Company discovered that the Original Form 6-Ks inadvertently incorporated by reference Exhibits 99.1-99.4 to this Form 6-K into the Company's Registration Statement on Form F-10 (File No. 333-289139).


    INCORPORATION BY REFERENCE

    Exhibits 99.1-99.4 to this Form 6-K are hereby incorporated by reference into the Company's Registration Statement on Form F-10 (File No. 333-292294).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

        CYBIN INC.  
        (Registrant)  
             
    Date: March 5, 2026 By: /s/ Greg Cavers  
        Name: Greg Cavers  
        Title: Chief Financial Officer  


    EXHIBIT INDEX

    99.1 News Release dated February 10, 2026 (incorporated by reference to Exhibit 99.1 to the Company's Form 6-K filed with the Securities and Exchange Commission on February 10, 2026)
       
    99.2 Interim Consolidated Financial Statements for the three and nine months ended December 31, 2025 (incorporated by reference to Exhibit 99.1 to the Company's Form 6-K filed with the Securities and Exchange Commission on February 13, 2026)
       
    99.3 Management's Discussion and Analysis for the three and nine months ended December 31, 2025 (incorporated by reference to Exhibit 99.2 to the Company's Form 6-K filed with the Securities and Exchange Commission on February 13, 2026)
       
    99.4 News Release dated February 13, 2026 (incorporated by reference to Exhibit 99.5 to the Company's Form 6-K filed with the Securities and Exchange Commission on February 13, 2026)


    Get the next $HELP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HELP

    DatePrice TargetRatingAnalyst
    2/2/2026$22.00Buy
    Jefferies
    More analyst ratings

    $HELP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

    GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions NEW YORK, March 5, 2026 /CNW/ -- Market News Updates News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news for millions of people dealing with constant worry and stress. Traditional medications like anti-anxiety drugs and antidepressants still play a big role, but therapy options such as cognitive-behavioral therapy and mindfulness techniques are also helping people manage symptoms without relying only on medication. Digital mental health tools and telehealth visits are making treatment easier to access, especially f

    3/5/26 9:30:00 AM ET
    $ACHC
    $AIFF
    $BWAY
    Medical Specialities
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

    Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale ("HAM-A") of ~10 points on top of Standard of Care ("SoC") at 6 weeksDurable effects sustained through at least 6 monthsIn Phase 1 trial most participants were ready for discharge within 3 hours1; Acute effects lasted ~90 minutesGenerally well-tolerated, adverse events were transient, with no drug related serious adverse events recordedAt six months, the pooled study population showed 67% responders and 39% of patients were in remission (see Figure 1 below) Figure 1 This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement date

    3/5/26 7:30:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

    Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).

    2/27/26 11:44:00 AM ET
    $ATAI
    $DFTX
    $GHRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $HELP
    SEC Filings

    View All

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    3/5/26 7:54:06 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    3/5/26 6:04:24 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cybin Inc.

    6-K - CYBIN INC. (0001833141) (Filer)

    2/24/26 5:17:07 PM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Helus Pharma with a new price target

    Jefferies initiated coverage of Helus Pharma with a rating of Buy and set a new price target of $22.00

    2/2/26 6:51:26 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HELP
    Leadership Updates

    Live Leadership Updates

    View All

    Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee

    In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company developing NSAs for serious mental health conditions, today announced the appointment of Dr. Freda Lewis-Hall, DFAPA, MFPM, to its Board of Di

    2/24/26 7:45:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

    - Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events -- Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder ("GAD") expected in Q1 2026 - This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. BOSTON and TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- HELUS PharmaTM (NASDAQ:HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists ("NSAs"), today re

    2/13/26 7:31:19 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

    Former President of Shire PLC's ("Shire") Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLCProven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system ("CNS") programsAppointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this year This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated

    2/10/26 7:30:00 AM ET
    $HELP
    Biotechnology: Pharmaceutical Preparations
    Health Care